Bristol Myers Squibb | World Briefings
Subscribe to World Briefings's newsletter

News Updates

Let's join our newsletter!

Do not worry we don't spam!

FDA Approves Cobenfy: First New Schizophrenia Treatment in 70 Years

Health

27 Sep, 2024

FDA Approves Cobenfy: First New Schizophrenia Treatment in 70 Years


The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s...

Immunotherapy Drugs Market Booming:  15.61% CAGR Forecast to 2031 - What's Driving This Growth?

Business

10 Aug, 2024

Immunotherapy Drugs Market Booming: 15.61% CAGR Forecast to 2031 - What's Driving This Growth?


Immunotherapy drugs are revolutionizing cancer treatment by harnessing the body's own immune system to target and destroy cancer cells. This...

Newsletter
Subscribe to Newsletter

Stay Tuned With Updates